Microbial platform technology for recombinant antibody fragment production: A review

Critical Reviews in Microbiology

Volumn 43, Issue 1, 2017, Pages 31-42

  Gupta, Sanjeev Kumar ^a   Shukla, Pratyoosh ^b  

^a IPCA Laboratories Ltd   (India)

^b MAHARSHI DAYANAND UNIVERSITY   (India)

Author keywords

Antibody fragments; bacterial platform; POP expression vector; recombinant antibody; secretary system

Indexed keywords

ENDOTOXIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; RECOMBINANT ANTIBODY; RECOMBINANT ANTIBODY FRAGMENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIGEN BINDING; BIOTECHNOLOGY; DIAGNOSIS; DRUG THERAPY; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MICROORGANISM; NONHUMAN; PRIORITY JOURNAL; RESEARCH; REVIEW; GENETICS; METABOLISM; MICROBIOLOGY;

ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; INDUSTRIAL MICROBIOLOGY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 85008426019     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2016.1150959     Document Type: Review

References (71)

1. Ahmad ZA, Yeap SK, Ali AM, et al. (2012). scFv antibody:principles and clinical application. Clin Dev Immunol 980250–15. ID doi:10.1155/2012/980250.
2. Baneyx F. (1999). Recombinant protein expression in Escherichia coli. Curr Opin Biotechnol 10:411–21.
3. Basu A, Li X, Leong SS. (2011). Refolding of proteins from inclusion bodies:rational design and recipes. Appl Microbiol Biotechnol 92:241–51.
4. Bradbury A, Velappan N, Verzillo V, et al. (2003). Antibodies in proteomics I:generating antibodies. Trends Biotechnol 21:275–81.
5. Bundy BC, Swartz JR. (2011). Efficient disulfide bond formation in virus-like particles. J Biotechnol 154:230–9.
6. Challener C. (2015). Fermentation for the future. BioPharm Int 28:1.
7. Chan CEZ, Lim APC, Chan AHY, et al. (2010). Optimized expression of full-length IgG1 antibody in a common E. coli strain. PLoS One 5:e10261. doi:10.1371/journal.pone.0010261.
8. Choi JH, Lee SY. (2004). Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol 64:625–35.
9. DePalma A. (2014). Advances in protein expression. Genet Eng Biotechnol News 34.
10. Fisher AC, Haitjema CH, Guarino C, et al. (2011). Production of secretory and extracellular N-linked glycoproteins in Escherichia coli. Appl Environ Microbiol 77:871–81.
11. Frenzel A, Hust M, Schirrmann T. (2013). Expression of recombinant antibodies. Front Immunol 4:217.
12. Goerke AR, Swartz JR. (2008). Development of cell-free protein synthesis platforms for disulfide bonded proteins. Biotechnol Bioeng 99:351–67.
13. Goshima N, Kawamura Y, Fukumoto A, et al. (2008). Human protein factory for converting the transcriptome into an in vitro-expressed proteome. Nat Methods 5:1011–7.
14. Groff D, Armstrong S, Rivers PJ, et al. (2014). Engineering toward a bacterial “endoplasmic reticulum” for the rapid expression of immunoglobulin proteins. mAbs 6:671–8.
15. Gupta SK, Shukla P. (2015). Advanced technologies for improved expression of recombinant proteins in bacteria:perspectives and applications. Crit Rev Biotechnol. [Epub ahead of print]. doi:10.3109/07388551.2015.1084264.
16. Hanagata H, Mizukami M, Miyauchi A. (2014). Efficient expression of antibody fragments with the Brevibacillus expression system. Antibodies 3:242–52.
17. Herrington-Symes AP, Farys M, Khalili H, Brocchini S. (2013). Antibody fragments:prolonging circulation half-life special issue-antibody research. Adv Biosci Biotechnol 4:689–98.
18. Hirayama C, Sakata M. (2002). Chromatographic removal of endotoxin from protein solutions by polymer particles. J Chromatogr B Analyt Technol Biomed Life Sci 781:419–32.
19. Holliger P, Hudson PJ. (2005). Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126–36.
20. Holms WH. (1986). The central metabolic pathways of Escherichia coli:relationship between flux and control at a branch point, efficiency of conversion to biomass, and excretion of acetate. Curr Top Cell Regul 28:69–105.
21. Huang CJ, Lin H, Yang X. (2012). Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 39:383–99.
22. Hudson PJ. (1998). Recombinant antibody fragments. Curr Opin Biotechnol 9:395–402.
23. Hust M, Jostock T, Menzel C, et al. (2007). Single chain Fab (scFab) fragment. BMC Biotechnol 7:14.
24. Jermutus L, Christ D. (2012). Expression of high-affinity human antibody fragments in bacteria. Nat Protocols 7:2.
25. Jiang X, Ookubo Y, Fujii I, et al. (2002). Expression of Fab fragment of catalytic antibody 6D9 in an Escherichia coli in vitro coupled transcription/translation system. FEBS Lett 514:290–4.
26. Jordan E, Al-Halabi L, Schirrmann T, Hust M. (2009). Antibody production by the Gram-positive bacterium Bacillus megaterium. Methods Mol Biol 525:509–16.
27. Joosten V, Lokman C, Hondel CAMJJ van den, Punt PJ. (2003). The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact 2:1.
28. Jordan E, Al-Halabi L, Schirrmann T, et al. (2007). Production of single chain Fab (scFab) fragments in Bacillus megaterium. Microb Cell Fact 6:38.
29. Katzen F, Peterson TC, Kudlicki W. (2009). Membrane protein expression:no cells required. Trends Biotechnol 27:455–60.
30. Katzen F, Chang G, Kudlicki W. (2005). The past, present and future of cell-free protein synthesis. Trends Biotechnol 23:150–6.
31. Kipriyanov SM, Moldenhauer G, Little M. (1997). High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J Immunol Methods 200:69–77.
32. Klima G. (2011). Expression of an antibody fragment utilizing the Pfenex expression technology platform, PEGS summit. Boston (MA):Boehringer-Ingelheim Pharmaceuticals.
33. Knapp KG, Goerke AR, Swartz JR. (2007). Cell-free synthesis of proteins that require disulfide bonds using glucose as an energy source. Biotechnol Bioeng 97:901–8.
34. Khodabakhsh F, Zia MF, Moazen F, et al. (2013). Comparison of the cytoplasmic and periplasmic production of reteplase in Escherichia coli. Prep Biochem Biotechnol 43:613–23.
35. Levy R, Ahluwalia K, Bohmann DJ, et al. (2013). Enhancement of antibody fragment secretion into the Escherichia coli periplasm by co-expression with the peptidyl prolyl isomerase, FkpA, in the cytoplasm. J Immunol Methods 394:10–21.
36. Levy R, Weiss R, Chen G, et al. (2001). Production of correctly folded Fab anti-body fragment in the cytoplasm of Escherichia coli trxBgor mutants via the coexpression of molecular chaperones. Protein Expr Purif 23:338–47.
37. Lin MF, Williams C, Murray MV, Ropp PA. (2005). Removal of lipopolysaccharides from protein-lipopolysaccharide complexes by nonflammable solvents. J Chromatogr B Analyt Technol Biomed Life Sci 816:167–74.
38. Lizak C, Fan YY, Weber TC, Aebi M. (2011). N-Linked glycosylation of antibody fragments in Escherichia coli. Bioconjug Chem 22:488–96
39. Magalhães PO, Lopes AM, Mazzola PG, Jr, et al. (2007). Methods of endotoxin removal from biological preparations:a review. J Pharm Pharm Sci 10:388–404.
40. Miethe S, Meyer T, Wöhl-Bruhn S, et al. (2012). Production of single chain fragment variable (scFv) antibodies in Escherichia coli using the LEX™ bioreactor. J Biotechnol 163:105–11.
41. Makrides SC. (1996). Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol Rev 60:512–38.
42. Mamat U, Wilke K, Bramhill D, et al. (2015). Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. Microbial Cell Factories 14:57.
43. Merk H, Gless C, Maertens B, et al. (2012). Reports:cell-free synthesis of functional and endotoxin-free antibody Fab fragments by translocation into microsomes. BioTechniques 53:153–60.
44. Merk H, Stiege W, Tsumoto K, et al. (1999). Cell-free expression of two single-chain monoclonal antibodies against lysozyme:effect of domain arrangement on the expression. J Biochem 125:328–33.
45. Monnier PP, Vigouroux RJ, Tassew NG. (2013). In-vivo applications of single chain Fv (variable domain) (scFv) fragments. Antibodies 2:193–208.
46. Nelson AL. (2010). Antibody fragments:hope and hype. MAbs 2:77–83.
47. Nelson AL, Reichert JM. (2009). Development trends for therapeutic antibody fragments. Nat Biotechnol 27:331–7.
48. Pissarra PN. (2000). Recombinant DNA proteins for the biopharmaceutical industry and the future for E. coli. Nat Biotechnol 18:831–3.
49. Retallack D, Coleman R. (2011). Achieving optimal expression for Fabs. GEN Tutorial 31:13.
50. Rosano GL, Ceccarelli EA. (2014). Recombinant protein expression in Escherichia coli:advances and challenges. Front Microbiol 4:217.
51. Rouet R, Lowe D, Dudgeon K, et al. (2000). Effect of engineered cysteines on yield, solubility and activity in various recombinant antibody formats expressed in E. coli. J Immunol Methods 242:101–14.
52. Rusch SL, Kendall DA. (2007). Interactions that drive Sec-dependent bacter-ial protein transport. Biochemistry 46:9665–73.
53. Ryabova LA, Desplancq D, Spirin AS, Plückthun A. (1997). Functional antibody production using cell-free translation:effects of protein disulfide isomerase and chaperones. Nat Biotechnol 15:79–84.
54. Stech M, Kubick S. (2015). Cell-free synthesis meets antibody production:a review. Antibodies 4:12–33.
55. Stech M, Brödel AK, Quast RB, et al. (2013). Cell-free systems:functional modules for synthetic and chemical biology. Advances in Biochemical Engineering/Biotechnology. Berlin, Heidelberg:Springer-Verlag, 67–102.
56. Stech M, Hust M, Schulze C, et al. (2014). Cell-free eukaryotic systems for the production, engineering and modification of scFv antibody fragments. Eng Life Sci 14:387–98.
57. Spadiut O, Capone S, Krainer F, et al. (2014). Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol 32:1.
58. Studier FW. (2005). Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 41:207–34.
59. Studier FW. (2014). Stable expression clones and auto-induction for protein production in E. coli. Methods Mol Biol 1091:17–32.
60. Skerra A, Pluckthun A. (1998). Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240:1038–41.
61. Song HN, Jang JH, Kim YW, et al. (2014). Refolded scFv antibody fragment against myoglobin shows rapid reaction kinetics. Int J Mol Sci 15:23658–71.
62. Terpe K. (2006). Overview of bacterial expression systems for heterologous protein production:from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 72:211–22.
63. Thie H, Binius S, Schirrmann T, et al. (2009). Multimerization domains for antibody phage display and antibody production. Nat Biotechnol 26:314–21.
64. Tseng TT, Tyler BM, Setubal JC. (2009). Protein secretion systems in bacterial-host associations, and their description in the gene ontology. BMC Microbiol 9:S2.
65. Wacker’s esetec. (2005). Case study–antibody fragment Esetec enables high yield production of an active antibody fragment. Wacker’s Biologics.
66. Walsh G. (2010). Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917–92.
67. Wong MS, Wu S, Causey TB, et al. (2008). Reduction of acetate accumulation in Escherichia coli cultures for increased recombinant protein production. Metab Eng 10:97–108.
68. Xu Y, Lee J, Tran C, et al. (2015). Production of bispecific antibodies in “using a cell-free expression system” using a cell-free expression. mAbs 7:231–42.
69. Yin G, Garces ED, Yang J, et al. (2012). Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system. mAbs 4:217–25.
70. Yin G, Swartz JR. (2004). Enhancing multiple disulfide bonded protein folding in a cell-free system. Biotechnol Bioeng 86:188–95.
71. Zawada JF, Yin G, Steiner AR, et al. (2011). Microscale to manufacturing scale-up of cell-free cytokine production–a new approach for shortening protein production development timelines. Biotechnol Bioeng 108:1570–8.